Hi, I'm Monica Laronda. I'm a professor at Lurie Children's Hospital in Chicago and Northwestern University. I am the current basic science chair for the ENDO 2025 annual meeting here in San Francisco.So, the trends that we're seeing at ENDO 2025, it's probably not surprising, but along the lines of obesity, especially with the increase of GLP-1 drugs. And, but of course, because we're the Endocrine Society, we're looking at new emerging research in this field, how it might affect puberty, the onset of menarche and chronic health in individuals that have increased BMI, increased adiposity or variations in their genetic makeup that maybe expose them to or induce some of these mechanisms and how this affects their life overall.I'm personally really excited about the abstract presented by Dr. Xin Hu, PhD, who's a trainee in Professor Barbara Cohn's lab at Emory University. They're going to be discussing the transmission of environmental health and the rise of the cross-generational effects and how this might affect age at menarche. So again, this is like extra environmental influences on puberty development in menarche.One of the Meet the Scientist sessions is going to talk about serendipitous discoveries of sex differences in research. And so, this one is going to be given by Dr. Cha and she's from Vanderbilt University and some of the discoveries that she's made in glycemic phenotypes. She happened to find differences in male and female mice. And so, this one will be just an exciting way of like describing how to select and analyze this data as sex as a biological variable.And I think it's really important, especially in this climate to remind people that these are important differences that should be studied and realized because it really does help us understand not just the onset of disease, but how to treat these disorders. And often these are quite translatable into the human population.Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in MenMy name is Shellsea Portillo and I'm a newly graduated endocrinologist from St. Louis University Hospital in St. Louis, Missouri.We conducted a retrospective cohort study of 234 adult men treated with GLP-1 based therapies, including semaglutide, tirzepatide, and dulaglutide. 79 % had diabetes, and a baseline BMI was 32.5.We reviewed charts of men who had total and or free testosterone levels measured before and after treatment, and who were not receiving testosterone supplements.The background is that obesity and type 2 diabetes are associated with low testosterone, often due to central suppression of the hypothalamic-pituitary-gonadal (HPG) axis. It is known that weight loss improves testosterone levels, and GLP-1 therapies are widely used for weight reduction in patients with obesity and diabetes.With therapy, patients lost about 10 % of their weight and A1C improved. Total and free testosterone improved significantly and the total proportion of men with total T greater than 300 nanograms per deciliter increased from 54% to 76%.That means we had an increase, an absolute increase, of 22%. We observed a significant inverse correlation between weight loss and change in total testosterone. But the number of subjects with repeated free T measurements was unlimited, raising the possibility of a type 2 error.These findings suggest that GLP-1-based weight loss therapy may not only improve metabolic outcomes but also bring testosterone level back to a normal range in men with obesity or type 2 diabetes.This could offer a non-hormonal approach to improving testosterone in a specific population where low T is often due to weight-related suppression of the hormonal axis.As for next steps, the current study was retrospective, and while it was a clear association, more research is needed, ideally prospective trials to confirm these findings.This study was not designed or intended to support FDA-approved approval of GLP-1 receptor agonist as a treatment for hypogonadism. However, these findings opened the door to future research. .Sign up for our weekly HealthDay newsletter